Epstein-Barr Virus Specific Immunotherapy
/ Dana-Farber Cancer Institute
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 14, 2022
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
(clinicaltrials.gov)
- P2 | N=18 | Completed | Sponsor: Dana-Farber Cancer Institute | Active, not recruiting ➔ Completed
Trial completion • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1